Pyc Therapeutics Ltd has released a press release.
PYC Nominates Fourth Clinical Drug Candidate in PMS Program
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- PYC to Progress Kidney Drug Candidate Into Human Trials
- Consolidation/Split - PYC
- RP11 SRC Approves Dose Escalation to Final Patient Cohort
- First ADOA Patient Dosed in Clinical Trial
- Interim Update on Progress in RP11 Repeat Dose Trials
Later from PYC Therapeutics
- US FDA Grants Rare Pediatric Disease Designation to VP-001
- ADOA Safety Review Committee Approves Dose Escalation
- Approval to Commence Human Trials in Kidney Program
- PYC Equity Raising to Raise up to $146 Million
- PYC Equity Raising Presentation
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics